| Research and Practice in Thrombosis and Haemostasis | |
| Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study | |
| Stéphanie Cloutier1  Darius Wrathall2  Brian M. Feldman2  Victor S. Blanchette2  Saunya Dover2  Eleanor Pullenayegum2  Byron Song2  Daniel Kazandjian2  Anthony K. Chan3  Sara J. Israels4  Geroges E. Rivard5  Ann Marie Stain6  Nicole Laferriere7  John K. M. Wu8  Robert J. Klaassen9  Sue Ann Hawes1,10  Elizabeth Paradis1,11  Roona Sinha1,12  MacGregor Steele1,13  | |
| [1] Centre de l'hémophilie de l'est du Québec Hôpital de l’Enfant‐JésusUniversité Laval Québec QC Canada;Child Health Evaluative Sciences The Hospital for Sick Children Toronto ON Canada;Department of Pediatrics McMaster Children’s Hospital McMaster University Hamilton ON Canada;Department of Pediatrics and Child Health University of Manitoba Winnipeg MB Canada;Division of Hematology/Oncology Department of Pediatrics CHU Sainte‐Justine Montreal QC Canada;Division of Hematology/Oncology The Hospital for Sick Children Toronto ON Canada;Division of Hematology/Oncology Thunder Bay Regional Cancer Care Thunder Bay ON Canada;Division of Hematology/Oncology/BMT Department of Pediatrics UBC & BC Children’s Hospital Vancouver BC Canada;Division of Pediatric Hematology/Oncology Children’s Hospital of Eastern Ontario University of Ottawa Ottawa ON Canada;Division of Pediatric Hematology/Oncology IWK Health Centre Halifax NS Canada;Health Sciences North Sudbury ON Canada;Saskatchewan Bleeding Disorders Program Royal University Hospital Saskatoon SK Canada;Section of Pediatric Hematology Department of Pediatrics University of Calgary and Alberta Children’s Hospital Calgary AB Canada; | |
| 关键词: bleeding; factor VIII; hemophilia A; prophylaxis; treatment adherence and compliance; | |
| DOI : 10.1002/rth2.12301 | |
| 来源: DOAJ | |
【 摘 要 】
Abstract Background Standard of care for persons with severe hemophilia A includes regular replacement of factor VIII (FVIII). Prophylaxis regimens using standard half‐life (SHL) FVIII concentrates, while effective, are costly and require frequent intravenous infusions. Aim This study evaluated the adherence of 56 boys with severe hemophilia A to tailored, frequency‐escalated prophylaxis with an SHL recombinant FVIII concentrate. Methods We reviewed the factor infusion and bleeding logs of study subjects. Adherence to the prescribed regimen was calculated on a weekly basis, and bleeding rates were determined from self/proxy‐reported bleeding logs. The primary outcome was adherence to the prescribed prophylaxis regimen. Results The median (range of values [ROV]) weekly adherence to prophylaxis was 85.7% (37.4%‐99.8%). The median (ROV) adherent weeks on steps 1 (weekly), 2 (twice weekly), and 3 (alternate‐day) were 92.9% (50%‐100%), 80.3 (32%‐96%), and 72.6% (14%‐98%); relative to step 1, subjects were less likely to be adherent on steps 2 and 3 (P < 0.00). On step 1, our cohort had higher adherence than previously reported rates. The median (ROV) adherence to the breakthrough bleeding protocol was 47.1% (0%‐100%). At any given time, bleeding risk was reduced by 15% for each 10% increase in adherence during the preceding 12 weeks (hazard ratio, 0.85; 95% confidence interval, 0.81‐0.90). Conclusion This cohort had high rates of adherence to the prescribed prophylaxis regimen. Initiating prophylaxis with once‐weekly infusions facilitated adherence to the prophylaxis regimen in this cohort of boys with severe hemophilia A started on primary prophylaxis at a very young age.
【 授权许可】
Unknown